Clinical Oncology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Clinical Oncology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Cancers, Год журнала: 2024, Номер 16(3), С. 579 - 579
Опубликована: Янв. 30, 2024
Among neoplastic diseases, breast cancer (BC) is one of the most influenced by gender. Despite common misconceptions associating BC as a women-only disease, can also occur in men. Additionally, transgender individuals may experience BC. Genetic risk factors play relevant role predisposition, with important implications precision prevention and treatment. The genetic architecture susceptibility similar women men, high-, moderate-, low-penetrance variants; however, some sex-specific features have emerged. Inherited high-penetrance pathogenic variants (PVs) BRCA1 BRCA2 genes are strongest factor. PVs more commonly associated increased female male BC, respectively. Notably, BRCA-associated BCs characterized pathologic features. Recently, next-generation sequencing technologies helped to provide insights on moderate-penetrance variants, particularly PALB2, CHEK2, ATM genes, while international collaborative genome-wide association studies contributed evidence their combined effect polygenic models, modulators BRCA1/2 PV carriers. Overall, all these suggested that basis although similar, differ from Evaluating component distinct entity first step improve both personalized assessment therapeutic choices patients sexes order reach gender equality care. In this review, we summarize latest research field predisposition particular focus similarities differences discuss implications, challenges, open issues surround establishment gender-oriented clinical management for
Язык: Английский
Процитировано
16Technology in Cancer Research & Treatment, Год журнала: 2024, Номер 23
Опубликована: Янв. 1, 2024
Male breast cancer (MBC), one of the rare types among men where global incidence rate is 1.8% all cancers cases with a yearly increase in pace 1.1%. Since last 10 years, has been increased from 7.2% to 10.3% and mortality was decreased 11% 3.8%. Nevertheless, diagnoses expected be around 2.6% near future, still there great lack studies characterize MBC including developed countries. Based on our search, it evidenced literature that number risk factors for cause are significant, which includes age, family genetic history, mutations specific genes due various environmental impacts, hormonal imbalance unregulated expression receptors hormones high levels estrogen or androgen compared females. MBCs broadly classified into ductal lobular carcinomas further sub-types, some symptoms lump swelling breast, redness flaky skin irritation nipple discharge similar female (FBC). The most common diagnostic tools currently use ultrasound guided sonography, mammography, biopsies. Treatment modalities include surgery, radiotherapy, chemotherapy, therapy, targeted therapies. However, guidelines followed diagnosis treatment mostly based FBC prospective related MBC. distinct clinical molecular features MBC, need develop different methods more multinational approaches help oncologist improve care patients.
Язык: Английский
Процитировано
5Cancers, Год журнала: 2024, Номер 16(17), С. 3049 - 3049
Опубликована: Сен. 1, 2024
Breast cancer is one of the most common cancers and leading cause death in women. Less than 1% breast cases are male cancers. Although there has been significant progress made management cancer, due to its rarity among men, question whether men women with have same treatment response survival rate still needs be answered. The primary goal this study compare outcomes between female patients.
Язык: Английский
Процитировано
5Histopathology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 31, 2025
Atypical ductal hyperplasia (ADH) in male breast tissue is a rare condition with limited understanding. We aimed to elucidate the clinicopathological characteristics of ADH patients, focusing on its prevalence, presentation, and associated factors. analysed 40 cases from 1626 encountered between 2013 2023. Clinicopathological data were reviewed identify key features trends. The mean age patients our cohort was 43 years. mainly discovered incidentally during workup for gynecomastia 85% (34/40) cases. Only two cases, 5% (2/40), initially presented as palpable mass; one pure other an intraductal papilloma (IDP). Nipple discharge initial presentation 7.5% (3/40) all which IDP. Additionally, (2/40) identified due calcifications imaging. Excision diagnostic procedure 77.5% (31/40) core needle biopsy (CNB) 22.5% (9/40). In most 70% (28/40) had unilateral disease, while 84.4% (27/32) exhibited multifocal lesions, 90.6% (29/32) showed cribriform architectural patterns. Notably, 77.3% (17/22) history medications linked gynecomastia. During follow-up (9 months 26 years), developed carcinoma situ (DCIS). primarily presents alongside Multifocality patterns are common histological features. association medication-induced potential progression DCIS highlight clinical significance males.
Язык: Английский
Процитировано
0Viruses, Год журнала: 2022, Номер 14(8), С. 1704 - 1704
Опубликована: Авг. 1, 2022
A Human Betaretrovirus (HBRV) has been identified in humans, dating as far back about 4500 years ago, with a high probability of it being acquired by our species around 10,000 following jump from mice to humans. HBRV is the human homolog MMTV (mouse mammary tumor virus), which etiological agent murine tumors. The hypothesis HMTV (human virus) was proposed 50 and solid scientific basis during last 30 years, demonstration robust link breast cancer PBC, primary biliary cholangitis. This article summarizes most what known MMTV/HMTV/HBRV since discovery at beginning century, make evident both quantity quality research supporting existence its pathogenic role. Here, sufficient mention that evidence includes viral sequences have breast-cancer samples worldwide distribution, complete proviral genome cloned patients saliva contains HBRV, possible route inter-human infection. Controversies arisen concerning results obtained tissues, many them outdated new evidence, are critically discussed confuted.
Язык: Английский
Процитировано
19Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 27, 2025
Abstract The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description HER2 status was conducted. total 6,015 MBC patients from 45 studies and 135 with sequencing data were identified. positive rates hazard ratios (HR) for overall survival (OS) combined using Metaprop. prevalence + 10.0% (95% CI: 8.0-13.0%). Subgroup analyses showed that 7% 2.0-14.0%) had protein overexpression. 10% overexpression and/or gene amplification. Asian the highest incidence 17% 12.0-22.0%). fluctuated widely 2001 to 2015 then stabilized at 10%. positivity significantly correlated worse OS than negative ones (HR = 1.92, 1.47–2.51). proportion inconsistent results intrinsic HER2-enriched subtype. Altered genes MBC, such as ERBB2, AGO2, RECQL4, CLTC, not detected HER2-MBC. Genomic analysis revealed differences between those FBC. percentage slightly lower women. Multiple approaches may be needed jointly assess MBC.
Язык: Английский
Процитировано
0Medical radiology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0European Journal of Cancer Prevention, Год журнала: 2025, Номер unknown
Опубликована: Фев. 13, 2025
Male breast cancer (MBC) contributes to approximately 1% of total diagnoses, with rapidly rising incidence and mortality rates worldwide. Since most research has focused on women, this study intended report the incidence, mortality, disability-adjusted life years (DALYs) MBC aid in its control prevention. The data DALYs, deaths, age-standardized between 1990 2021 different countries territories were sourced from Global Burden Disease (GBD) study. In 2021, Eastern Sub-Saharan Africa had highest rates. Countries middle socio-demographic index quintile showed fastest growth rate, ASDR, ASMR. From DALYs increased Alcohol use, dietary risks, tobacco use risk factors for ASMR, risks ranking first all GBD regions. rise number cases men places substantial stress humans. Hence, policymakers should establish effective interventions strategies patients accordance local situation.
Язык: Английский
Процитировано
0Cancers, Год журнала: 2022, Номер 14(13), С. 3292 - 3292
Опубликована: Июль 5, 2022
Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BRCA2 gene; however, data regarding other BC predisposition genes are limited. In this retrospective multicenter study, we investigated PVs BRCA1/2 and 23 non-BRCA1/2 using sample 614 patients mBC, recruited through centers German Consortium for Hereditary Breast Ovarian Cancer. A proportion mBC carried (23.0%, 142/614) BRCA1 (4.6%, 28/614). The was 11.0% without family history and/or ovarian cancer. Patients did not show an earlier disease onset than those without. predominant clinical presentation tumor phenotypes estrogen receptor (ER)-positive, progesterone (PR)-positive, HER2-negative (77.7%); further, 10.2% tumors were triple-positive, 1.2% triple-negative. No association found between ER/PR/HER2 status PV occurrence. Comparing protein-truncating (PTVs) control (ExAC, n = 27,173) revealed significant associations PTVs both (BRCA1: OR 17.04, 95% CI 10.54−26.82, p < 10−5; BRCA2: 77.71, 58.71−102.33, 10−5). case-control investigation 340 BRCA1/2-negative ExAC controls CHEK2, PALB2, ATM (CHEK2: 3.78, 1.59−7.71, 0.002; PALB2: 14.77, 5.02−36.02, ATM: 3.36, 0.89−8.96, 0.04). Overall, our findings support benefit multi-gene panel testing irrespective their history, age at onset, phenotype.
Язык: Английский
Процитировано
18Journal of Breast Imaging, Год журнала: 2023, Номер 5(2), С. 104 - 111
Опубликована: Фев. 1, 2023
Abstract Breast cancer screening has been highly successful in women reducing mortality through early detection. In comparison, clinical detection of breast remains the norm men, and delay diagnosis is reflected by a persistent survival disparity compared to despite advances modern therapy. Male presents an interesting dilemma. While mammography sensitive specific for male cancer, routine not justified overall low disease incidence. Yet there interest leveraging targeted men with identifiable risk factors allow detection, data may support this approach. The purpose article explore potential utility examining unique biologic characteristics cancers that lend themselves mammographic We will also discuss available evidence outcomes summarize recent updates management recommendations Society guidelines.
Язык: Английский
Процитировано
9